IL-2 gene therapy of solid tumors: An approach for the prevention of signal transduction defects in T cells

Journal of Molecular Medicine

Volumn 74, Issue 3, 1996, Pages 127-134

  Zier, K S ^a   Gansbacher, B ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene therapy; Immune suppression; Interleukin 2; Signal transduction; T Cells

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; GENE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; FORECASTING; GENE THERAPY; HUMANS; INTERLEUKIN-2; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0029947360     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575444     Document Type: Review

References (79)

1. Pardoll D (1994) A new look for the 1990s. Nature 369:357-358
2. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4
3. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 12:337-365
4. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGown P, Linsley PS (1994) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
5. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci 90:5687-5690
6. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7-1 costimulation on T cell mediated tumor immunity. J Exp Med 179:523-532
7. + T cells by B7-transfected melanoma cells. Science 259:368-370
8. George AJT, Stevenson FK (1989) Prospect for the treatment of B cell tumors using idiotypic vaccination. Intern Rev Immunol 4:271-310
9. Sulizeanu D (1993) Immunosuppressive factors in human cancers. Adv Cancer Res 60:247-267
10. Browning MJ, Bodmer WF (1992) MHC antigens and cancer: Implications for T-cell surveillance. Curr Opin Immunol 4:613-618
11. Broder S, Waldmann H (1978) The suppressor cell network in cancer. New Engl J Med 299:1281-1284
12. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor bearing mice. Science 258:1795-1798
13. Salvadori S, Gansbacher B, Pizzimenti A, Zier K. (1994) Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors. J Immunol 153:5176-5182
14. Pardoll DM (1993) Cancer vaccines. Immunol Today 14:310-316
15. Rosenthal F, Zier KS, Gansbacher B (1994) Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity. Curr Opin Oncol 6:611-615
16. Letourneur F, Klausner RD (1992) Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science 255:79-82
17. Zier KS (1985) Generation of antigen specific CTL directed against class II molecules expressed by activated T cells. J Immunol Methods 84:73-84
18. Berke G (1994) The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Ann Rev Immunol 12:735-773
19. June CH, Bluestone JA, Nadler L, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15:321-331
20. Lindsten T, June CH, Ledbetter JA, Stella GT, Thompson CB (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244: 339-343
21. Jenkins MK, Johnson JG (1993) Molecules involved in T cell costimulation. Curr Opin Immunol 5:361-367
22. Livingston PO (1991) Active specific immunotherapy in the treatment of cancer. In: Oettgen HF (ed) Immunology and allergy clinics of american: human cancer immunology II, vol 11. Saunders, London, pp 402-423
23. Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Topalian SL, Schwawrtzentruber KJ, Weber JS, Ettingausen SE, Parkinson DN, White DE (1993) The development of gene therapy for the treatment of cancer. Ann Surg 218:455-463
24. Colombo MP, Forni G (1993) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48-51
25. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by the IL-2 gene. J Immunol 149:3627-3635
26. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher G, Schaffner G, Birnstiel ML (1995) Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci 92:4711-4714
27. Mulligan RC (1993) The basic science of gene therapy. Science 260:926-932
28. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
29. Golumbek PT, Lazenby A J, Levitzky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer engineered to secrete interleukin-4. Science 254:713-716
30. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177:1127-1134
31. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky HI, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci 90:3539-3543
32. Porgardor A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Anti-metastatic vaccination of tumor-bearing mice with two types of IFN-γ gene inserted tumors cells. J Immunol 150:1458-1470
33. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503-512
34. Fearon E R, Pardoll D M, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
35. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990) Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res 50:7820-7825
36. Golumbek PT, Lazenby A J, Levitzky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer engineered to secrete interleukin-4. Science 254:713-716
37. Blankenstein T, Qin ZH, Uberia K, Muller W, Rosen H, Volk HD, T Diamantstein (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173:1047-1052
38. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA (1991) Murine tumor cells transduced with the gene for tumor necrosis factor alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146:3227-3234
39. + T cell-dependent tumor rejection. J Exp Med 174:1291-1298
40. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Scared E-L (1991) Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 21:851-854
41. Colombo M, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G (1991) Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173:889-897
42. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L. (1992) Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers therapeutic competence against metastatic cells. Cancer Res 52:3679-3686
43. Salvadori, S, Gansbacher, B, Wernick, I, Tirelli, S, Zier, K (1995) B7-1 transfected tumor cells induce a response in syngeneic hosts in vivo, but fail to stimulate naive allogeneic cells in vitro. Human Gene Ther 6:1299-1306
44. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of hone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
45. Sanders ME, Makgoba MW, June CH, Young HA, Shaw S (1989) Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. Eur J Immunol 19:803-807
46. Isakov N, Wange RL, Samelson LE (1994) The role of tyrosine kinases and phosphotyrosine-containing recognition motifs in regulation of the T cell-antigen receptor mediated signal transduction pathway. J Leuk Biol 55:265-271
47. Minami T, Kono T, Miyazaki T, Taniguehi T (1993) The IL-2 receptor complex: its function, and target genes. Ann Rev Immunol 11:245-268
48. Samelson LE, Klausner RD (1992) Tyrosine kinases and tyrosine-based activation motifs. Current research on activation via the T cell antigen receptor. J Biol Chem 267:24913-24916
49. van Oers S, Killeen N, Weiss A (1994) ZAP-70 is constitutively associated with tyrosine-phosphorylated TCR zeta in murine thymocytes and lymph node T cells. Immunity 1:675-685
50. Salvadori S, Zier K (1996) The molecular basis of T cell dysfunction in cancer is influenced by paracrine secretion of tumor-derived IL-2. J Immunol (in press)
51. Weiss A, Littman DR (1994) Signal transduction by lymphocyte antigen receptors. Cell 76:263-274
52. lck. Nature 357:161-164
53. Appelby MW, Gross JA, Cooke, MP Levin SD, Qian X, Perlmutter RM (1992) Defective T cell receptor signaling in mice lacking the thymic isoform of p59-fyn. Cell 70:751-763
54. Chan AC, Iwashima M, Turck CW, Weiss A (1992) ZAP-70: a 70 kD protein-tyrosinase that associates with the TCR ζ chain. Cell 71:649-662
55. Wange RL, Malek SN, Desiderio S, Samelson LE (1993) Tandem SH2 domains of ZAP-70 bind to the T cell antigen receptor zeta and CDε from activated Jurkat T cells. J Biol Chem 268: 19797-19801
56. + thymic selection in humans lacking ZAP-70 kinase. Cell 76:947-958
57. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, Parslow TE (1994) Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 264:1596-1599
58. lck regulates the activity of phosphatidylinositol-3′-kinase in IL-2 dependent T cells. J Biol Chem 268:20031-20036
59. Karnitz LM, Sutor SL, Abraham RT (1994) The src-family kinase, fyn, regulates the activation of phosphatidylinositol-3-kinase in an IL-2 dependent line. J Exp Med 179:1799-1808
60. Gaulton GN, Williamson P (1994) Interleukin-2 and the Interleukin-2 receptor complex. In: Samelson LE (ed) Lymphocyte activation. Karger, Basel, pp 91-114
61. Truitt KE, Hicks CM, Imboden JB (1994) Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med 179:1071-1076
62. August A, Dupont B (1994) CD28 of T lymphocytes associates with Pl 3-kinase. Int Immunol 6:769-774
63. Mills GB, Schmandt R, Gibson S, Leung B, Hill M, May C, Shi YF, Branch DR, Radvanyi L, Truitt KE, Imboden J (1993) Transmembrane signaling by the IL-2 receptor: progress and conundrums. Semin Immunol 5:345-364
64. ras during T-cell activation and growth. Immunol Today 16:159-164
65. Reed JC, Nowell PC (1988) Mechanisms of interleukin 2 action: IL-2-inducible gene expression in T lymphocytes. In: Smith KA (ed) Interleukin 2, pp 137-151
66. Johnston JA, Kawamura M, Kirken RA, Chen Y, Blake T, Shibuya D, Ortaldo J, McVicar D, O'Shea J (1994) Phosphorylation and activation of the Jak-3 kinase in response to interleukin-2. Nature 370:151-153
67. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu KT, Ihle JN (1994) Involvement of the Jak-3 kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370:153-157
68. Beadling C, Guschin D, Witthuhn BA, Ziemiecki A, Ihle JN, Kerr IM, Cantrell DA (1994) Activation of JAK kinases and STAT proteins by interleukin-2 and interferon α, but not the T cell antigen receptor, in human T lymphocytes. EMBO J 13: 5605-5615
69. Hou H, Schindler U, Henzel WJ, Wong SC, McKnight SL (1995) Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 2:321-329
70. Darnell JE, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421
71. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:613-5616
72. Nakagomi H, Peterson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling, R (1993) Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
73. Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F (1994) The decreased expression of CD3 ζ chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 59:752-755
74. Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881-1886
75. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL (1994) Alterations in NκB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969-2972
76. Li X, Liu J, Park JK, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs R, Bukowski R, Finke J (1994) T cells from renal carcinoma patients exhibit an abnormal pattern of κB-specific DNA-binding activity: a preliminary report. Cancer Res 54:5424-5429
77. Salvadori S, Gansbacher B, Zier KS (1994) Functional differences are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells. Cancer Gene Ther 1:165-170
78. Zier K, Gansbacher B, Salvadori S (1995) Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 17:39-45
79. Mackay CR, Marston WL, Dudler L (1990) Naive and memory T cell show distinct pathways of lymphocyte recirculation. J Exp Med 171:801-817